Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Castle Biosciences, Inc.

< Previous 1 2 3 4 Next >
Castle Biosciences’ DecisionDx®-Melanoma Test Receives 2022 MedTech Breakthrough Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data Demonstrating DecisionDx®-Melanoma’s Ability to Risk-Stratify Patients According to Melanoma-Specific Survival to be Shared during the 2022 ASCO Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
TissueCypher® Outperforms Pathologist Diagnoses When Predicting Progression in Patients Diagnosed with Barrett’s Esophagus with Low-Grade Dysplasia
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data from Second Independent Multi-Center Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Confirms Independent Risk-Stratification Performance of DecisionDx®-SCC
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Collaborates with The Sun Bus to Provide Free Skin Cancer Screenings
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Reports First Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Camille Schrier, Miss America 2020, and Castle Biosciences Partner to Expand Awareness of Genetic Testing in Depression and Anxiety
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Recognizes Skin Cancer Awareness Month through Its Support of Patient-Focused Initiatives
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Expanded U.S. Federal Supply Schedule Contract Covering Its Entire Dermatologic Cancer Portfolio of Tests
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data from Independent, Pooled Analysis Show Significantly Improved Risk Predictions Over Clinical Variables for TissueCypher® Barrett’s Esophagus Test and Ability to Identify Patients at High Risk of Progressing to Esophageal Cancer
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Completes Acquisition of AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release First Quarter 2022 Financial Results and Host Conference Call on Monday, May 9
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx®-Melanoma Tested Patients Compared to Untested Patients
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present Data at the 18th European Association of Dermato Oncology (EADO) Congress
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data on Its Inflammatory Skin Disease Pipeline Test at the 4th Annual Revolutionizing Atopic Dermatitis (RAD) Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 21st Annual Needham Virtual Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Acquire AltheaDx
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Receives Advanced Diagnostic Laboratory Test (ADLT) Status for TissueCypher® Barrett’s Esophagus Test from the Centers for Medicare & Medicaid Services (CMS)
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data to be Presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting Demonstrate Ability of DecisionDx®-Melanoma and DecisionDx®-SCC to Inform Clinical Decision Making
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences to Present at the 24th Annual Needham Growth Conference
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Completes Acquisition of Cernostics
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio
From Castle Biosciences, Inc.
Via Business Wire
Tickers CSTL
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS